Clinical trial NCT01165021 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, folic acid, vitamin b12, dexamethasone
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, [C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Nonsquamous Non-Small Cell Lung Cancer that was confirmed by tissue biopsy

          -  Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2)

          -  Tumor considered potentially resectable

          -  Good performance status (score of 0 or 1) according to Eastern Cooperative Oncology
             Group scale (ECOG)

          -  No prior therapy for lung cancer

          -  Measurable disease according to version 1.1 of Response Evaluation Criteria in Solid
             Tumors (RECIST) Criteria

          -  Life expectancy of at least 6 months

          -  Organs are functioning well (bone marrow reserve, liver, kidney, lung)

          -  Signed Informed Consent

          -  Women must be surgically sterile, postmenopausal, or compliant with a medically
             approved contraceptive regimen (for example, intrauterine device, birth control pills,
             or barrier device) during and for 6 months after last dose of study drug; must have a
             negative pregnancy test within 7 days before study enrollment; and must not be
             breast-feeding.

          -  Men must be surgically sterile, or compliant with a contraceptive regimen during and
             for 6 months after last dose of study drug.

          -  Be fit for surgery at the time of enrollment

        Exclusion Criteria:

          -  Receiving or have received an investigational drug or device within the last 30 days

          -  Have previously completed or withdrawn from this study or any other study
             investigating pemetrexed

          -  Serious concomitant systemic disorder

          -  Serious cardiac condition, such as myocardial infarction within 6 months, angina, or
             heart disease

          -  Receiving concurrent administration of any other anticancer therapy

          -  Have received a recent (within 30 days of enrollment) or are receiving concurrent
             yellow fever vaccination

          -  Inability or unwillingness to take Pemetrexed supplementation/premedication (folic
             acid, vitamin B12, or corticosteroids)

          -  Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other
             than an aspirin dose less than or equal to 1.3 grams per day